We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Matritech, a developer of proteomics-based diagnostic products, has entered
into an agreement providing for a $12.55 million private placement for the sale
of 1,426,124 shares of its Series A Convertible Preferred Stock, each share
of which is convertible into 10 shares of common stock, and five-year warrants
to purchase 4,991,382 shares of common stock at an exercise price of $1.47 per
share.
Images, a provider of enterprise-wide advanced visualization software,
is introducing ViTALCardia, a technology solution designed specifically for
cardiologists. ViTALCardia includes high-powered software for diagnosis as well
as a Web-based thin-client distribution technology to provide access to images
throughout the cardiology enterprise.
IRIS International, a manufacturer and marketer of
automated IVD urinalysis systems and medical devices used in hospitals and reference
clinical laboratories worldwide, has announced the launch and first shipment
of its iQ200 Sprint, the fastest automated urine microscopy analyzer on the
market.
William Wijns, the co-principal investigator of the Endeavor II pivotal clinical
trial and co-director of the Cardiovascular Center, OLV Ziekenhuis, Aalst, Belgium,
presented positive results of the Endeavor II trial at the American College
of Cardiology 54th Annual Scientific Session.
Conor Medsystems presented angiographic and clinical data from the company's
pivotal EuroSTAR study evaluating its CoStar cobalt chromium paclitaxel-eluting
stent in a complex patient cohort.
Results from the REALITY trial presented at the American College of Cardiology
Annual Scientific Session found that Cordis' Cypher Sirolimus-eluting Coronary
Stent was associated with development of significantly fewer blood clots at
the stent site (stent thromboses) than the Boston Scientific/Angiotech Taxus
Paclitaxel-eluting Coronary Stent.
Ophthonix, a vision care company developing a "high-definition" vision
technology that provides consumers with superior optical clarity and crispness
compared to any other available vision corrections, has hired Thomas George
as chief financial officer (CFO) to oversee all financial controls, organization
and relationships.
Genpathway announced the availability of its novel tools enabling discovery
and characterization of differential gene transcription, components and processes
for gene regulation and corresponding genetic pathways.